Table 4. Clinical data of 15 patients with available data at 4 weeks after treatment.
| Patients | Age, yr | Gender | Genotype | HCV RNA at baseline, IU/mL | HCV Ag at baseline, fmol/L | HCV RNA at 4weeks, IU/mL | HCV Ag at 4weeks, fmol/L | Treatment response |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | 34 | F | 1 | 22,400,000 | 17,139.56 | 49,000 | 140.16 | SVR |
| Patient 2 | 43 | M | 1 | 11,700,000 | 14,444.98 | Not detectable | Not detectable | SVR |
| Patient 3 | 56 | F | 2 | 14,800,000 | 13,998.37 | Not detectable | Not detectable | SVR |
| Patient 4 | 27 | F | 1 | 825,000 | 1,605.15 | 718 | Not detectable | SVR |
| Patient 5 | 40 | M | 1 | 18,900,000 | 14,314.95 | 193 | Not detectable | SVR |
| Patient 6 | 45 | M | 2 | 34,500 | 120.95 | Not detectable | Not detectable | SVR |
| Patient 7 | 41 | M | 2 | 181,000 | 269.02 | Not detectable | Not detectable | SVR |
| Patient 8 | 69 | F | 2 | 3,110,000 | 321.87 | Not detectable | Not detectable | SVR |
| Patient 9 | 19 | M | 2 | 372,000 | 2,950.81 | Not detectable | Not detectable | SVR |
| Patient 10 | 47 | F | 2 | 2,190,000 | 3,096.32 | Not detectable | Not detectable | SVR |
| Patient 11 | 65 | F | 2 | 8,850,000 | 17,394.41 | 232 | Not detectable | Relapse |
| Patient 12 | 55 | M | 2 | 318,000 | 812.54 | 32.5 | Not detectable | SVR |
| Patient 13 | 54 | M | 2 | 43,900 | 134.99 | Not detectable | Not detectable | SVR |
| Patient 14 | 64 | M | 2 | 86,300 | 435.4 | Not detectable | Not detectable | SVR |
| Patient 15 | 50 | F | 2 | 569,000 | 1,804.14 | 769 | 55.83 | No response |
HCV, hepatitis C virus; HCV Ag, HCV core antigen; SVR, sustained virologic response.